<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862875</url>
  </required_header>
  <id_info>
    <org_study_id>RRL-01-2009</org_study_id>
    <nct_id>NCT00862875</nct_id>
  </id_info>
  <brief_title>Levemir-Body Composition and Energy Metabolism</brief_title>
  <official_title>Effects of Basal Insulin Analogue Detemir on Body Composition, Epicardial Fat and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives is to compare the changes in body composition (primary objective), diabetes&#xD;
      parameters, energy expenditure and energy intake between Insulin detemir (Levemir® - Novolin®&#xD;
      4 pen) and insulin glargine (Lantus® - Solostar®) both in combination with Metformin and&#xD;
      insulin secretagogues (SU) between baseline and after 6 months of insulin therapy in 80 type&#xD;
      2 diabetic patients failing on oral diabetic agents .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in total fat mass (in kg)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epicardial fat, trunk fat, total fat free mass, weight &amp; waist circumference, HbA1c, fasting glucose, RMR, TEF,PAEE &amp; TEE, energy intake.</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1:Insulin detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin detemir (Levemir® - Novolin® 4 pen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:Insulin Glargin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine (Lantus® - Solostar®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir or Glargine</intervention_name>
    <description>Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.</description>
    <arm_group_label>1:Insulin detemir</arm_group_label>
    <arm_group_label>2:Insulin Glargin</arm_group_label>
    <other_name>Detemir</other_name>
    <other_name>Levemir</other_name>
    <other_name>Long acting insulin</other_name>
    <other_name>Bed time insulin</other_name>
    <other_name>Lantus</other_name>
    <other_name>basal insulin analogue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetic patients who require basal (long-acting) insulin for the control of&#xD;
             hyperglycemia according to the opinion of the investigator.&#xD;
&#xD;
          -  Inadequate Glucose control: Hemoglobin A1c (HbA1c) percentage in the range of ≥ 7.5 -&#xD;
             12.0%&#xD;
&#xD;
          -  Stable body weight for previous 3 months (± 5 kg).&#xD;
&#xD;
          -  Structured exercise lower than 4 hours per week.&#xD;
&#xD;
          -  Metformin ≥1.5 g/day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical, social or geographic condition, which, in the opinion of the investigator&#xD;
             would not allow safe or reliable completion of the protocol.&#xD;
&#xD;
          -  Type 1 Diabetes Mellitus&#xD;
&#xD;
          -  Previous treatment with insulin (&lt; 6 months prior inclusion). Insulin therapy for less&#xD;
             than 6 days at the time of an acute event is acceptable.&#xD;
&#xD;
          -  Secondary diabetes mellitus (i.e. steroid induced, Cushing syndrome, chronic&#xD;
             pancreatitis, cystic fibrosis, etc.) and maturity-onset diabetes of the young&#xD;
&#xD;
          -  Proliferative retinopathy/maculopathy requiring treatment&#xD;
&#xD;
          -  Hypoglycemia unawareness or recurrent major hypoglycaemia&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
&#xD;
          -  Unstable coronary artery disease&#xD;
&#xD;
          -  Heart Failure as defined by class IV according to NYHA classification&#xD;
&#xD;
          -  Recent (&lt; 6 months) history of myocardial infarction, stroke or T.I.A, ventricular&#xD;
             arrhythmias, or unstable supra-ventricular arrhythmias.&#xD;
&#xD;
          -  Renal Insufficiency. Creatinine clearance &lt; 40 ml/min (MDRD formula).&#xD;
&#xD;
          -  Acute (&lt; 2 months) or Chronic infectious diseases requiring either hospitalization or&#xD;
             antibiotic treatment for more than 2 weeks&#xD;
&#xD;
          -  Recent (&lt; 1 year) diagnosis of systemic malignancies except thyroid and skin cancer&#xD;
&#xD;
          -  Major psychiatric diseases&#xD;
&#xD;
          -  History of drug addiction&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Medication that affects weight such as&#xD;
&#xD;
               -  Systemic corticosteroids (prednisone)&#xD;
&#xD;
               -  Anti-obesity medication (Xenical® or Meridia®)&#xD;
&#xD;
               -  Megace ®&#xD;
&#xD;
               -  Antidepressant medication associated with significant weight impact such as&#xD;
                  Zyprexa®, Remeron® based on investigator judgment.&#xD;
&#xD;
               -  Growth hormone therapy or testosterone supplementation should be initiated for at&#xD;
                  least 6 months and at stable dose for 3 months prior to enrolment&#xD;
&#xD;
               -  Medication that affects glycemic control and hypoglycemic unawareness based on&#xD;
                  investigator judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Rabasa-Lhoret, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherches Cliniques de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherches Cliniques de Montreal</investigator_affiliation>
    <investigator_full_name>Rémi Rabasa-Lhoret</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Insulin initiation</keyword>
  <keyword>oral therapy failure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

